Pot shortages could be dire at Washington's
Pot shortages could be dire at Washington's stores
Associated Press
By GENE JOHNSON 15 hours ago
Spokane Co. pot producer expects one ounce to cost $700
.
SPOKANE COUNTY, Wash.--A pot producer’s crop in North Spokane County was on track on Friday to become some of the first marijuana produced and sold in Washington State for recreational use.
Frank Schade owns the Green Surfer and said he would be ready to serve retail stores opening on July 8, 2014.
"Just about anybody that wants to buy a little is probably going to be able to,” said Schade.
Schade said marijuana would be expensive for the first few months in Washington State. He said it would cost around $25 per gram or $700 for an ounce. The legal limit a person can buy at a time is one ounce.
"The price for the novelty is going to be steep,” said Schade.
The marijuana starts as a seed in a nursery at the Green Surfer. It then grows to the right size and finally is cut and dried to send off to processors.
"Plants in this part of the marijuana farm need to be under the light at all times. As you can see here, they use a variety of lights to create an effect like they're under the sun,” said Schade.
Schade said he expected the supply would run out after it first went on sale and that there would a pot shortage for about one month. He said he thought the initial excitement about buying marijuana would be too much demand.
"I think there's going to be a quick run for all of the available product,” said Schade.
Schade expected to produce 20 to 30 pounds of marijuana each month. He said in time he expected the market to adjust so that there would be a steady supply of pot for anyone that wanted it.
SEATTLE (AP) — Randy Oliver has a pressing question as legal marijuana sales are about to begin in Washington state: Where's all the weed?
Oliver is the chief scientist at Analytical 360 in Yakima, the only lab that has been certified to test the heavily taxed marijuana that will wind up on store shelves next month. So far, just two licensed growers have turned in samples for testing, with another due to turn in a small batch next week, he told The Associated Press on Saturday.
"There's such a small stream of samples coming through," he said. "There's going to be some long lines and some high prices."
The state's Liquor Control Board has been warning of shortages when the first stores open. The board plans to issue the first 15 to 20 retail licenses July 7, with shops allowed to open the next day if they're ready. It's not clear how many that will be. Board staff said at a meeting last week that only one store in Seattle is ready for its final inspection.
Only 79 of the more than 2,600 people who applied for marijuana growing licenses last fall have been approved, and many of them aren't ready to harvest.
"Will there be shortages?" Randy Simmons, the board's legal-pot project manager, said in a recent AP interview. "The answer to that is yes."
But the figures provided by Oliver on Saturday suggest just how serious those shortages could be. The samples provided to Analytical 360 represent a maximum harvest so far of 190 pounds — and Oliver said he expects 20 to 30 percent of the samples to fail because of high mold counts. Marijuana associated with those samples can't be sold as dried bud, but can be used to make cannabis oil.
The amount harvested so far "isn't going to stay on the shelves very long," Oliver said.
Oliver said he's worried that his lab could see a crush of samples provided in the days before the first stores open, swamping his lab and delaying the arrival of product on store shelves.
"We can probably handle 100 samples a day, but if we get 300 samples thrown at us?" he said. "I'm worried about everybody coming to us at the last minute."
Growers have to provide samples for every strain of cannabis they grow, and for every five pounds of flowers they harvest.
Oliver also said glitches with the software the state is using to track the bar-coded marijuana from clone to sale could compound the issue. He said his lab has had trouble entering test results in the program, and some marijuana that passed has shown up as having failed. It took one grower five days to provide the samples to the lab because of software problems, he said, characterizing the bugs as nothing unusual for a new program.
It isn't clear how soon other labs might be certified or be ready to handle samples. Seattle's Sea of Green Farms is one of the two growers who have had their pot tested. Bob Leeds, a partner there, confirmed that as of Saturday, the only certified lab that shows up in the tracking system is Analytical 360.
The other grower tested is Spokane's Kouchlock Productions. Kouchlock and Sea of Green were among the very first growers licensed back in March.
Spokesmen for the liquor board did not immediately return a call or emails on Saturday.
The Sea of Green team was spending the weekend packaging the approximately 40 pounds of marijuana it harvested recently, Leeds said. It has contracts with four shops to sell most of it already — for an exorbitant $4,000 a pound. That's nearly $9 per gram before the retailer's mark-up, 25 percent retail excise tax, and state and local sales taxes. At the state's unlicensed medical dispensaries, cannabis often sells for $8 to $12 per gram.
"When people start calling we have to tell them we're not going to have anything for them until August," Leeds said. "That's a long way off when you're trying to open a business."
___
l.yimg.com
LikeLike · · Share
Howard Haftel
Write a comment...
Scroll down for more posts ▼
Top 10 Most Recent News Articles
ZEISS Sets Sights on China’s Myopia Epidemic They're calling myopia a public health crisis in China, and if you've seen the statistics, that's no exaggeration. Enter ZEISS Medical Technology, angling for a piece of the pie with their newly NMPA-approved PT LUNANA phakic intraocular lens. This is more than just another medical product, folks. It's a strategic entry into...
Continue Reading
A Strong Quarter Despite Some Knocks It ain't every day you see a company like Keenova Therapeutics clocking solid top-line growth, despite battling the waves of operational losses. Now, don't get me wrong; I ain't swooning over their near $96 million loss from continuing operations, but let me give credit where it's due—those sales numbers popped impressive. Pillars of...
Continue Reading
Graphene Making Waves in Defense Fresh off the press, folks. First Graphene Limited is struttin' onto the US defense scene with a repeat order for its PureGRAPH®—a big deal in the realm of electrically conductive inks. The tally comes to around A$35,000 in an order from a longtime American customer. We're talking about inks that print circuits, sensors, and more,...
Continue Reading
Hunting for the Perfect Gift? Look No Further The holiday hustle and bustle inevitably sparks one of the annual dilemmas: What on earth should you buy those grandkids of yours? No need to get all twisted up this season. Enter ZestYears, the savvy go-to guide for grandparents who want to nail gift-giving without breaking a sweat or the bank. These folks, based out of...
Continue Reading
If you've ever punched numbers on car values, you've probably bumped into Kelley Blue Book. This icon in vehicle valuation is marking its 100th birthday with a bang—road-tripping across Route 66 to sprinkle some joy across the dusty roads of history. Nostalgia Meets the Open Road The legendary Route 66 is not just the backdrop but the beating heart of this centennial...
Continue Reading
Building Bridges Between Work and Home Well, it’s about time someone threw in a lifeline to those drowning in Florida’s housing crisis. Tampa General Hospital, teaming up with The Michaels Organization, is setting the stage with 'The Linden': a solution pitched smack dab into the heart of affordability woes. This isn't your run-of-the-mill press release fluff. They've...
Continue Reading
Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...
Continue Reading
Partnership to Expand Digital Asset Liquidity Looks like Caladan and NextBlock just threw their hats in the ring to shake up South Korea’s institutional digital asset market. These two big guns have cooked up a strategic collaboration, aiming to bring more global liquidity into the mix. Dive into what this means for the digital asset scene in South Korea. Why This Move...
Continue Reading
Blazing a New Trail in Automotive Excellence Who would've thought rubber on road could hit a jaw-dropping 503.17 km/h (312.65 mph)? Giti Tire just broke the mold, etching its name into the history books with the Guinness World Records™ title for their GitiSport e.GTR2 Pro tires. This isn't just about speed—it's about engineering marvel and pushing boundaries in...
Continue Reading
Why Your Vision Might Be Blurry: It's Not Always Simple Dr. Spencer Franz isn’t just another face behind an optometry chart. He’s tackling a topic as blurry as it is relatable—your vision. You'd think a simple tweak of your glasses script might do the trick, but surprise, surprise, vision issues are sneakier than that. Changes in prescriptions are a dime a dozen,...
Continue Reading
Top 5 Most Recently Viewed Articles
Assessing Cresco Labs: A Promising Investment Prospect With the cannabis market continuing to evolve, Cresco Labs Inc. stands out as an intriguing option for investors. Despite a backdrop of flat earnings and ongoing market challenges, analysts emphasize that Cresco (CRLBF) is holding the line as an "Overweight" stock. A recent analysis reveals Cresco's substantial...
Continue Reading
Context Therapeutics Releases First Quarter 2025 Financial Results Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, made significant strides in Q1 2025, especially with its two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials. As of March 31, 2025, the company reported...
Continue Reading
Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...
Continue Reading
Wood Partners Begins Construction on Alta Flatirons The 251-unit apartment community is one of the last remaining parcels of the Downtown Superior Masterplan. Overview of Alta Flatirons National multifamily developer Wood Partners has officially commenced the development of Alta Flatirons, a significant project located in a suburb near Boulder. This community, which will...
Continue Reading
Adobe Unveils Exciting New AI-Driven Marketing Tools Adobe Systems Incorporated (NASDAQ: ADBE) has just rolled out a game-changing suite of updates to its Adobe Experience Cloud services. These innovations are designed to help brands enhance the performance of their AI-generated marketing content significantly. With a focus on advanced analytics and the ability to...
Continue Reading